Clinical Trial

An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
CHO-V08 is currently being developed as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes. The goal of study (KLEBBI-001) is to evaluate the safety, reactogenicity, and immunogenicity of the preventive vaccine of CHO-V08 in healthy volunteers aged from 18 to 50 years old.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-10.
Status change: Not Yet Recruiting → Recruiting 2025-06-26
Trial Details
NCT Number NCT07016152
Lead Sponsor Cho Pharma Inc.
Conditions Klebsiella Pneumoniae Infection, Vaccine
Enrollment 40 participants
Start Date 2025-06-26
Primary Completion 2026-11-05 (estimated)
Study Completion 2027-04-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-27